| Market Capitalization (Millions $) |
641 |
| Shares
Outstanding (Millions) |
164 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-49 |
| Cash Flow (TTM) (Millions $) |
-92 |
| Capital Exp. (TTM) (Millions $) |
0 |
Savara Inc
Savara Inc is a clinical-stage biopharmaceutical company that is involved in the development of novel therapies for patients suffering from rare respiratory diseases. The company's primary focus is on conducting research and development programs targeted at designing and commercializing innovative treatment options for rare pulmonary conditions.
The company was founded in 2006 and is headquartered in Austin, Texas, USA. It operates as a public company, listed on the NASDAQ stock exchange under the symbol "SVRA." Savara Inc has a workforce of over 40 employees and is led by its executive team comprised of seasoned healthcare professionals with a track record of success in the industry.
Savara is currently engaged in several clinical development programs targeting cystic fibrosis (CF), a rare genetic disorder that affects the lungs and other organs. One of its key programs is molgramostim (GM-CSF) inhalation solution, which is aimed at treating patients with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease that affects only a few thousand people worldwide.
Other programs that Savara is working on include Aironite, an aerosol formulation targeted at treating several pulmonary indications characterized by inflammation and mucus hypersecretion, and AeroVanc, an inhaled vancomycin-based treatment designed for treating Methicillin-resistant Staphylococcus aureus (MRSA) lung infections in patients with CF.
Savara's platform technology enhances the delivery of inhaled medications, combining unique formulations with novel precision drug-delivery technologies to improve efficacy, safety, convenience, and patient outcomes.
To attract strategic partners and investors, Savara has entered into several collaborations and funding arrangements with leading healthcare organizations and industry partners. Most recently, the company partnered with the Cystic Fibrosis Foundation to advance its AeroVanc program's clinical development.
In summary, Savara Inc is a clinical-stage biopharmaceutical company involved in the development of innovative therapeutic solutions for rare respiratory diseases using its proprietary platform technology. Through its partnerships with leading healthcare organizations, the company is making significant strides towards providing effective treatment options to patients with rare pulmonary conditions, where there are currently limited treatment options.
Company Address: 1717 Langhorne Newtown Road Langhorne 19047 PA
Company Phone Number: 614-1848 Stock Exchange / Ticker: NASDAQ SVRA
| SVRA is expected to report next financial results on March 29, 2024. |
|
|
